Steve Shuey
About Steve Shuey
Steve Shuey serves as the Executive Director of Clinical Operations at Travere Therapeutics, where he has been since 2022. He has extensive experience in clinical operations, having previously held senior roles at notable companies such as Biogen Idec, Halozyme Therapeutics, and IGNYTA, and has a strong background in oncology and rare disease studies.
Current Role at Travere Therapeutics
Steve Shuey serves as the Executive Director of Clinical Operations at Travere Therapeutics since 2022. In this role, he oversees clinical operations and strategy, focusing on the development of therapies for rare diseases. His leadership is instrumental in guiding clinical trials and ensuring compliance with regulatory standards.
Previous Experience at Travere Therapeutics
Before his current position, Steve Shuey worked at Travere Therapeutics as the Senior Director of Clinical Operations from 2018 to 2022. During this time, he led a global team to successfully enroll participants in the largest Phase III study for focal segmental glomerulosclerosis (FSGS), achieving a database lock in less than six weeks from the last patient visit.
Professional Background in Clinical Operations
Steve Shuey has extensive experience in clinical operations, having held various leadership roles in notable companies. He worked at Biogen Idec for 23 years, where he progressed from Associate Director to Sr. Clinical Program Leader. He also served as Director of Clinical Operations at IGNYTA, Inc. and Halozyme Therapeutics, Inc., focusing on oncology and rare disease clinical trials.
Education and Specialization
Steve Shuey earned a Bachelor of Science degree in Genetics from the University of California, Davis. His educational background supports his specialization in oncology development and rare disease clinical operations, contributing to his ability to manage complex clinical studies across multiple regions, including the US, UK, Asia, and South America.
Achievements in Clinical Development
Throughout his career, Steve Shuey has successfully led multiple cross-functional clinical development teams, resulting in several successful Investigational New Drug (IND) filings. His recognition for managing both local and global teams highlights his capability to build effective relationships within and outside organizations.